Literature DB >> 27734750

Association of anandamide with altered binocular depth inversion illusion in schizophrenia.

Anne R Reuter1, J Malte Bumb1, Juliane K Mueller1, Cathrin Rohleder1, Franziska Pahlisch1, Franziska Hanke1, Elisabeth Arens2, F Markus Leweke1, Dagmar Koethe3, Emanuel Schwarz1.   

Abstract

OBJECTIVES: Binocular depth inversion illusion (BDII) represents an illusion of visual perception that involves higher-order visual and cognitive processes. Its impairment has been linked to psychotic conditions and identified as a marker for at-risk mental states. The endogenous cannabinoid system (ECS) is involved in various neurophysiological processes. One of its key components, anandamide, is involved in the pathophysiology of schizophrenia. Little is known about its impact on BDII alterations. Therefore, we explored associations between BDII and anandamide levels.
METHODS: BDII was conducted and blood and CSF were taken in 28 first-episode antipsychotic-naïve schizophrenia (SZ) patients and 81 healthy controls (HC). Serum and CSF anandamide levels were determined by high-performance liquid chromatography/mass spectrometry.
RESULTS: BDII scores were significantly elevated in SZ versus HC, indicating a disruption of illusionary revision of percepts in SZ. Anandamide levels were significantly higher in CSF of SZ compared to HC, while serum anandamide was not. However, we found specific association differences of anandamide levels and BDII scores between schizophrenia patients and controls in serum.
CONCLUSIONS: These findings support the hypothesis of an involvement of anandamide in cognitive processes impaired in schizophrenia and are consistent with a protective effect of elevated anandamide levels herein.

Entities:  

Keywords:  BDII; Binocular depth inversion illusion; anandamide; endocannabinoids; schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27734750     DOI: 10.1080/15622975.2016.1246750

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  9 in total

1.  Neural correlates of binocular depth inversion illusion in antipsychotic-naïve first-episode schizophrenia patients.

Authors:  Cathrin Rohleder; Dagmar Koethe; Stefan Fritze; Cristina E Topor; F Markus Leweke; Dusan Hirjak
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-03-19       Impact factor: 5.270

Review 2.  Cannabinoids and glial cells: possible mechanism to understand schizophrenia.

Authors:  Valéria de Almeida; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-01       Impact factor: 5.270

Review 3.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

4.  Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis.

Authors:  Amedeo Minichino; Morwenna Senior; Natascia Brondino; Sam H Zhang; Beata R Godwlewska; Philip W J Burnet; Andrea Cipriani; Belinda R Lennox
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

Review 5.  Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review.

Authors:  Timothy A Couttas; Beverly Jieu; Cathrin Rohleder; F Markus Leweke
Journal:  Front Psychiatry       Date:  2022-05-27       Impact factor: 5.435

6.  Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting.

Authors:  Stéphane Potvin; Louiza Mahrouche; Roxane Assaf; Marjolaine Chicoine; Charles-Édouard Giguère; Alexandra Furtos; Roger Godbout
Journal:  Front Psychiatry       Date:  2020-06-30       Impact factor: 4.157

Review 7.  Cannabidiol as a potential treatment for psychosis.

Authors:  Cathy Davies; Sagnik Bhattacharyya
Journal:  Ther Adv Psychopharmacol       Date:  2019-11-08

Review 8.  Cannabinoids, reward processing, and psychosis.

Authors:  Brandon Gunasekera; Kelly Diederen; Sagnik Bhattacharyya
Journal:  Psychopharmacology (Berl)       Date:  2021-03-01       Impact factor: 4.415

Review 9.  Endocannabinoid system in psychotic and mood disorders, a review of human studies.

Authors:  Ranjini Garani; Jeremy J Watts; Romina Mizrahi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-09-06       Impact factor: 5.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.